Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mo | Magnasense AB: The Letter of Intent with Subgen AI Limited regarding reverse takeover has been extended | 61 | GlobeNewswire (Europe) | Magnasense AB ("Magnasense" or the "Company") announces a further extension of the Letter of Intent regarding a potential reverse takeover (the "Transaction") with Subgen AI Limited ("Subgen"), a UK-based... ► Artikel lesen | |
Mo | Magnasense AB: Magnasense AB files appeal against decision by Swedish Financial Supervisory Authority | 44 | GlobeNewswire (Europe) | Magnasense AB has today filed an appeal with the Administrative Court in Stockholm against the decision by the Swedish Financial Supervisory Authority (Finansinspektionen) dated 25 June 2025 regarding... ► Artikel lesen | |
07.07. | Magnasense AB: Vasiliki Fragkou Resigns from her position as Chief Operating Officer of Magnasense AB and as a director of AegirBio UK Ltd. | 59 | GlobeNewswire (Europe) | Magnasense/AegirBio UK Ltd. announces that Vasiliki Fragkou has officially stepped down from her position.
We would like to sincerely thank Vasiliki for her dedication and contributions during her time... ► Artikel lesen | |
29.06. | Magnasense AB: The Letter of Intent with Subgen AI Limited regarding reverse takeover has been extended | 73 | GlobeNewswire (Europe) | Magnasense AB ("Magnasense" or the "Company") announces an extension of the Letter of Intent regarding a potential reverse takeover (the "Transaction") with Subgen AI Limited ("Subgen"), a UK-based... ► Artikel lesen | |
25.06. | Magnasense AB: Magnasense AB receives decision on penalty fee from the Swedish Financial Supervisory Authority | 164 | GlobeNewswire (Europe) | The Swedish Financial Supervisory Authority ("SFSA") has decided to impose a fine of SEK 12 million on Magnasense AB ("Magnasense" or the "Company") for violations of MAR.
On 14 April 2023, the SFSA... ► Artikel lesen | |
10.06. | Magnasense AB receives observation status | 136 | GlobeNewswire | Today, June 10, 2025, Magnasense AB (the "Company") issued a press release with information that the Company has signed a letter of intent regarding a reverse takeover of SUBGEN AI LIMITED.
According... ► Artikel lesen | |
10.06. | Magnasense AB: Magnasense enters into Letter of Intent with Subgen AI Limited regarding a reverse takeover | 116 | GlobeNewswire (Europe) | Magnasense AB ("Magnasense" or the "Company") announces today that the Company has entered into a non-binding letter of intent ("Letter of Intent") with SUBGEN AI LIMITED, registration number 15374966... ► Artikel lesen | |
MAGNASENSE Aktie jetzt für 0€ handeln | |||||
05.05. | Magnasense AB: Interview with Magnasense: Key Insights from the RADx Initiative | 190 | GlobeNewswire (Europe) | Q: Could you tell us about the primary goal of the RADx initiative and the role Magnasense played in it? A: The RADx initiative aimed to develop a Multiplex Diagnostic Platform that could detect COVID-19... ► Artikel lesen | |
28.04. | Magnasense AB: Magnasense AB Targets Gum Disease Market with Groundbreaking Diagnostic Technology - Capital Raise Underway to Accelerate Entry in High-Value Underserved Market | 112 | GlobeNewswire (Europe) | Magnasense AB, an innovator in smart diagnostics, is preparing to enter one of the largest yet underserved healthcare markets: periodontal (gum) disease. Magnasense is currently advancing its digital... ► Artikel lesen | |
24.04. | Magnasense AB: Overview of the Rights Issue in Magnasense AB | 131 | GlobeNewswire (Europe) | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, HONG KONG, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND... ► Artikel lesen | |
22.04. | Magnasense AB: Magnasense AB Develops Innovative Saliva Test for Gum Disease Detection | 141 | GlobeNewswire (Europe) | Rights Issue to Support Development of Groundbreaking Diagnostic Tool
Magnasense AB, a company specializing in rapid diagnostics, is in the process of developing a non-invasive saliva-based test designed... ► Artikel lesen | |
22.04. | Magnasense AB: Magnasense AB publishes information memorandum due to upcoming rights issue of units | 153 | GlobeNewswire (Europe) | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, HONG KONG, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND... ► Artikel lesen | |
17.04. | XFRA CAPITAL ADJUSTMENT INFORMATION - 17.04.2025 | 456 | Xetra Newsboard | Das Instrument 52Q SE0014401121 MAGNASENSE AB EQUITY wird ex Kapitalmassnahme gehandelt am 17.04.2025 The instrument 52Q SE0014401121 MAGNASENSE AB EQUITY is traded ex capital adjustment on 17.04.2025Das... ► Artikel lesen | |
10.04. | Magnasense AB: Magnasense resolves on the previously announced rights issue of units of a minimum of approx. MSEK 15 and a maximum of approx. MSEK 26.7 to develop saliva-based diagnostics as an alternative to blood testing | 86 | GlobeNewswire (Europe) | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, HONG KONG, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND... ► Artikel lesen | |
05.03. | Magnasense AB: Magnasense Interim Report October - December 2024 | 143 | GlobeNewswire (Europe) | "We are expanding our product capabilities as well as advancing solutions that are directly aligned with our professional market focus in oral health." Marco Witteveen, CEO of Magnasense AB
October... ► Artikel lesen | |
28.02. | XFRA CAPITAL ADJUSTMENT INFORMATION - 28.02.2025 | 241 | Xetra Newsboard | Das Instrument 7OK MHY641771016 OKEANIS ECO TANK. DL-,001 EQUITY wird cum Kapitalmassnahme gehandelt am 28.02.2025 und ex Kapitalmassnahme am 03.03.2025 The instrument 7OK MHY641771016 OKEANIS ECO TANK.... ► Artikel lesen | |
15.11.24 | Magnasense AB: Magnasense Interim Report July - September 2024 | 260 | GlobeNewswire (Europe) | "We are expanding our product capabilities as well as advancing solutions that are directly aligned with our professional market focus in oral health." Marco Witteveen, CEO of Magnasense AB
July - October... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
FRESENIUS | 40,890 | -0,87 % | Aktie von Fresenius SE & Co. KGaA heute am Aktienmarkt kaum gefragt: Kurs fällt (41,21 €) | An der deutschen Börse notiert die Fresenius SE & Co. KGaA-Aktie derzeit ein wenig leichter. Die Aktie notiert zur Stunde bei 41,21 Euro. Der Anteilsschein von Fresenius+Co KgaA verzeichnet aktuell... ► Artikel lesen | |
SIEMENS HEALTHINEERS | 46,110 | -1,03 % | EQS-CMS: Siemens Healthineers AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Siemens Healthineers AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b), Abs. 3 der Verordnung (EU) Nr. 596/2014, zuletzt geändert durch die Verordnung... ► Artikel lesen | |
FRESENIUS MEDICAL CARE | 45,940 | -1,40 % | DAX tiefer, Bitcoin, Silber stark: BASF, Lufthansa, BMW, Rheinmetall, FMC, Siemens Energy ... | Die Ankündigung von Donald Trump, Importe aus der EU ab 1. August mit einem Zoll in Höhe von 30 Prozent belegen zu wollen, hat beim DAX am Freitag Bremsspuren hinterlassen. Der deutsche Leitindex verabschiedete... ► Artikel lesen | |
GERRESHEIMER | 47,140 | -0,13 % | Spin-Off könnte Wende bringen: Kommt Gerresheimer raus aus dem Kurskeller? | © Foto: picture alliance/ASSOCIATED PRESS/Gerresheimer AG - picture alliance/ASSOCIATED PRESS/Gerresheimer AGNach der erneuten Senkung der Wachstumsprognose für das laufende Jahr haben die Aktien des... ► Artikel lesen | |
CARL ZEISS MEDITEC | 51,70 | +1,47 % | DEUTSCHE BANK RESEARCH stuft CARL ZEISS MEDITEC AG auf 'Hold' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Carl Zeiss Meditec vor der Quartalsbilanz mit einem Kursziel von 55 Euro auf "Hold" belassen. Der Medizintechnikhersteller... ► Artikel lesen | |
PROCEPT BIOROBOTICS | 58,34 | -1,00 % | Procept BioRobotics: BofA bestätigt Kaufempfehlung trotz geplanter Medicare-Kürzungen | ||
RXSIGHT | 7,350 | -0,41 % | Steris, Solventum upgraded, RxSight downgraded in Morgan Stanley's MedTech review | ||
UNITEDHEALTH | 242,95 | -0,10 % | Bank-Bilanzen im Fokus - Bitcoin, Nel, United Health, ASML, Goldman Sachs, BoA, Johnson & Johnson | Die Wall Street beendete den gestrigen Handelstag uneinheitlich. Während Standardwerte kaum gefragt waren, sorgte erneut der Technologiebereich für Bewegung. Der Nasdaq 100 stieg zur Eröffnung auf ein... ► Artikel lesen | |
ATRICURE | 29,260 | -1,65 % | AtriCure completes enrollment in stroke prevention trial | ||
GENEDX | 78,00 | -3,17 % | Rackspace US, Inc.: Rackspace Technology und Sema4.ai stellen die erste skalierbare KI-Agent-Lösung für Unternehmen vor | Die unternehmensgerechte Lösung schließt die Lücke zwischen KI-Experimenten und umfassender TransformationSAN ANTONIO, June 18, 2025®) und die Anwendungsmanagement-Expertise von Rackspace mit der fortschrittlichen... ► Artikel lesen | |
NUTEX HEALTH | 113,81 | +2,74 % | Nutex Health: Aktionäre wählen Vorstand und genehmigen Planänderungen auf Hauptversammlung | ||
DRAEGERWERK | 70,10 | +2,49 % | DAX-Check LIVE: BASF, Brenntag, Commerzbank, Drägerwerk, Mutares, Renk, Thyssenkrupp im Fokus | Der DAX schloss vor dem Wochenende mit einem Rückgang von 0,8 Prozent bei 24.255 Punkten. Trotz dieses Rücksetzers verzeichnete der deutsche Leitindex auf Wochensicht weiterhin ein Plus von zwei Prozent.... ► Artikel lesen | |
MIMEDX | 6,420 | -4,11 % | MiMedx Group, Inc: MIMEDX Comments on Proposed Medicare Reimbursement Rule Changes for CY 2026 | MARIETTA, Ga., July 15, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) ("MIMEDX" or the "Company") today commented on the Centers for Medicare and Medicaid Services ("CMS") release of... ► Artikel lesen | |
HIMS & HERS HEALTH | 43,220 | -0,25 % | Hims & Hers nach Aus mit Novo Nordisk: "Erhöhtes Risiko von Rechtsstreitigkeiten" | Wie gewonnen, so zerronnen: Zunächst entfachte die umfangreiche Zusammenarbeit zwischen dem Telehealth-Unternehmen Hims & Hers und dem Biopharma-Riesen Novo Nordisk jede Menge Euphorie. Doch dann kam... ► Artikel lesen | |
INCANNEX HEALTHCARE | 0,598 | +61,44 % | Incannex Healthcare Completes Phase 2 Enrollment in RePOSA Phase 2/3 Trial of IHL-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (OSA) | NEW YORK and MELBOURNE, Australia, April 03, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing... ► Artikel lesen |